Syncromune is a clinical stage biopharmaceutical dedicated to the development of better immunotherapies for metastatic solid tumors.
Syncromune has raised $100.0M in total funding. The most recent round was Series A. The last funding was announced in December 2024.
Syncromune's investors include Wasatch Equity Partners.
Syncromune is headquartered in Fort Lauderdale, United States.
Syncromune is a clinical stage biopharmaceutical dedicated to the development of better immunotherapies for metastatic solid tumors.
Syncromune is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Syncromune — Funding & Investors." VCBacked, December 20, 2024, https://www.vcbacked.co/company/syncromune. Accessed October 30, 2026.
VCBacked. (2024). Syncromune — Funding & Investors. Retrieved October 30, 2026, from https://www.vcbacked.co/company/syncromune
{{cite web |title=Syncromune — Funding & Investors |url=https://www.vcbacked.co/company/syncromune |website=VCBacked |access-date=October 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated